FR2432869A1 - Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium - Google Patents

Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Info

Publication number
FR2432869A1
FR2432869A1 FR7823315A FR7823315A FR2432869A1 FR 2432869 A1 FR2432869 A1 FR 2432869A1 FR 7823315 A FR7823315 A FR 7823315A FR 7823315 A FR7823315 A FR 7823315A FR 2432869 A1 FR2432869 A1 FR 2432869A1
Authority
FR
France
Prior art keywords
phosphorus
magnesium
pref
calcitonin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7823315A
Other languages
French (fr)
Inventor
Francine Caulin
Charles Alfred Dufoort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARMOUR MONTAGU LABORATOIRE
Original Assignee
ARMOUR MONTAGU LABORATOIRE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARMOUR MONTAGU LABORATOIRE filed Critical ARMOUR MONTAGU LABORATOIRE
Priority to FR7823315A priority Critical patent/FR2432869A1/en
Publication of FR2432869A1 publication Critical patent/FR2432869A1/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins

Abstract

Compsns. for the treatment of osteoporosis contain an association of calcination and phosphorus (e.g. inorganic phosphate such as sodium or mono-magnesium phosphate or glycine phosphate) and pref also contain magnesium. Pref. compsns. contain 1500-3000 Medical Research Council (MRC) units of calcitonin associated with 180-360 g of phosphorus (as element) and 18-36 g of magnesium. The effects of calcitonin and phosphorus cpds. on bone formation has been studied, the present invention shows that together they exert a synergistic effect. Admin. of calcitonin in short treatments (sequential treatment) diminishes osteoclastic activity and the duration of the inversion phase, stimulates osteoblastic activity and avoids the troubles of prolonged treatment (reduction of formation of Basic Multicellular Units (BMU)). Pref. 30-70 MRC units per day are injected for 5 days in each 3 week period, whilst 1-2 g of phosphorus (as element) and opt. 0.1-0.2 g of magnesium (as element) are administered each day (continuously), The phosphorus and opt. magnesium are usually administered orally. A usual treatment course is for a period of 4-8 months.
FR7823315A 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium Withdrawn FR2432869A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7823315A FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7823315A FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Publications (1)

Publication Number Publication Date
FR2432869A1 true FR2432869A1 (en) 1980-03-07

Family

ID=9211676

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7823315A Withdrawn FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Country Status (1)

Country Link
FR (1) FR2432869A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004402A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of osteoporosis
US5171583A (en) * 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5932252A (en) * 1988-10-21 1999-08-03 The Regents Of The University Of California Method and composition for treatment of osteoporosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2333515A1 (en) * 1975-12-01 1977-07-01 Henkel & Cie Gmbh Pharmaceutical compositions for the treatment of calcium metabolism disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2333515A1 (en) * 1975-12-01 1977-07-01 Henkel & Cie Gmbh Pharmaceutical compositions for the treatment of calcium metabolism disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004402A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of osteoporosis
US5171583A (en) * 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5932252A (en) * 1988-10-21 1999-08-03 The Regents Of The University Of California Method and composition for treatment of osteoporosis
US6027737A (en) * 1988-10-21 2000-02-22 The Regents Of The University Of California Treatment for osteoporosis using potassium salts

Similar Documents

Publication Publication Date Title
TW474825B (en) Novel oral pharmaceutical formulations with multiple unit tableted dosage form and their process for preparation
KR970009883B1 (en) Compositions comprising catecholic butanes for the treatment and prevention of solid tumor
GB2129691B (en) Devices for administering medicaments to patients
AU533491B2 (en) Bandage for administering drugs to the skin
IL65080D0 (en) Novel bandage for administering beneficial drug
NZ336428A (en) use of substituted pyrazolyl benzosulphonamides to treat inflammation
ES2070837T3 (en) New controlled release formulations of tetracycline compounds.
TW422707B (en) Dry mix formulation for bisphosphonic acids
Kaye et al. Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment.
DE3376387D1 (en) The use of gallium salts for the manufacture of pharmaceutical compositions for the treatment of disorders of calcium homeostasis
AU2671292A (en) Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases
EP0155344A3 (en) Skin treatment composition
MX9303969A (en) Phosphonates and use of nonsteroidal anti-inflammatory drugs do not to treat arthritis.
IL87488D0 (en) Pharmaceutical compositions for the topical treatment of conditions associated with photodamaged skin,comprising substituted propenyl phenyl derivatives
CA2046397A1 (en) Inflammatory bowel disease preventive and curative agents containing zinc l- carnosine salt or complex as active ingredient
JPH04342525A (en) Production of phospholipase a2 inhibitor
DE69309701T2 (en) Compositions with delayed active ingredient release for the treatment of periodontal diseases
JPS6197215A (en) Phospholipid-containing medicine composition
ES2172288T3 (en) Combination therapy comprising interferon alfa ribavirin and in patients who have undergone antiviral and having chronic hepatitis C infection.
AU570506B2 (en) Intra-pocket drug delivery devices for treatment of periodontal diseases
JPS63146815A (en) Ibuprofen-containing medicinal composition
ZA8400679B (en) Skin treatment composition
ES2082887T3 (en) Flupirtine in combination with antiparkinsonian to combat muscle spasms.
SE8703625D0 (en) New medical use
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d

Legal Events

Date Code Title Description
ST Notification of lapse